胶质母细胞瘤 z-bo 2020-10-23 332

　　In a new study, researchers from the University of Zurich, ETH Zurich, University Hospital Zurich, and the biotechnology company Philochem found that the fusion of cytokines and antibodies is an effective method for the treatment of mouse glioblastoma. Cell tumor is a type of brain cancer that is difficult to treat.

　　Is difficult to surgically remove, has many side effects, and the drug has little effect. In recent years, scientists have tried to use drugs that can warn of tumors in the immune system, but have failed. In this new study, these researchers tried another method of fusing cytokines and antibodies to attack tumors. They hope that the combination of the two can promote the immune system to attack the tumor more strongly and hopefully eliminate it. Cytokines are small proteins secreted by cells of the immune system. Their normal function is to send signals to other cells of the immune system. Antibodies are Y-type proteins produced by plasma cells. Plasma cells are the main force of the immune system, and the antibodies they produce can attack viruses and bacteria. In this new study, these researchers fused the L19 antibody with the cytokine TNF to form the immune cytokine (immune cytokine) L19TNF. The L19 antibody was chosen because previous research has shown that it can look for markers of glioblastoma.

　　They confirmed that L19TNF was injected into mice induced by glioblastoma and monitored its effect on this brain tumor. These researchers found that injecting this immune cytokine into experimental mice enhanced the immune response, which in some cases slowed the growth of tumors, while in other cases it reversed the growth. They found that the tumor had disappeared completely in some mice. These researchers also found some evidence of long-term stability. They have not found any evidence of harmful side effects. Then, they will begin testing to determine whether human clinical trials can begin as soon as possible.